RecruitingNot ApplicableNCT05662540
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma: a Prospective, Single-arm Clinical Study
Sponsor
Ruijin Hospital
Enrollment
40 participants
Start Date
May 26, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study intends to evaluate the application value of Positron Emission Tomography/Magnetic Resonance (PET/MR) in the staging and efficacy evaluation of NK/T cell lymphoma, aiming to explore a more accurate system for predicting the prognosis of patients and guiding the treatment.
Eligibility
Min Age: 14 YearsMax Age: 70 Years
Inclusion Criteria7
- Pathologically diagnosed NK/T-cell lymphoma based on the WHO classification 2016
- Age from 14 to 70 years-old
- ECOG 0-2 score
- Patients with a life expectancy of at least 6 months
- Patient has not been treated before for NK/T cell lymphoma
- Commit to abide by the research procedures and cooperate with the implementation of the whole process of research
- Written informed consent
Exclusion Criteria11
- \- Subjects who meet any of the following criteria are not eligible for study entry
- Diagnosed aggressive NK cell leukemia
- Pregnant or lactating women
- Liver and kidney insufficiency
- Other PET/MR contraindications:
- Those with implanted functional electronic devices such as cardiac pacemakers
- Carotid aneurysm clipping and other implants are ferromagnetic materials
- Implanted perfusion devices such as insulin perfusion pumps
- Those who do not cooperate in examinations such as coma, mental illness, and critically ill patients
- Those who are claustrophobic
- Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study
Interventions
DEVICEPositron Emission Tomography/Magnetic Resonance (PET/MR)
18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05662540
Related Trials
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
NCT071620121 location
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
NCT070006173 locations
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
NCT067324921 location
Circulating Tumor DNA in Peripheral T-cell Lymphomas
NCT063621481 location
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
NCT058338931 location